ClinicalTrials.gg

Program

FXS5626

A development code. Also written as “FXS5626 tablet”, “Intervention1: FXS5626 Tablets” and “Intervention2: FXS5626 Tablets”.

In Fosun Pharma's pipeline, TYK2/JAK1. Its studies are mostly in Uveitis · Vitiligo, led by Fosun Pharma.

Furthest: phase 3, since Sep 17, 20263 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma33 open or runningphase 3since Sep 17, 2026Mar 11, 2026Feb 28, 2027phase 2 · NCT07552012
  • Named in Fosun Pharma’s own pipeline as FXS5626 (TYK2/JAK1), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2026First study: phase 2 study in UveitisFirst studyNCT07552012 · 40 planned · China
  2. Jul 6, 2026Phase 1 study in Evaluation of QTc IntervalNCT07695779 · 28 planned · China
  3. Sep 17, 2026Phase 3 study in Non-segmental VitiligoPhase 3 reachedNCT07840820 · 480 planned · China

Ahead

  1. Feb 28, 2027Primary completion: phase 2 study in UveitisNCT07552012
  2. Nov 10, 2027Primary completion: phase 3 study in Non-segmental VitiligoNCT07840820

TargetBeta

“TYK2/JAK1”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
brepocitinibrulePfizerphase 325
delgocitinibruleLEO Pharmaphase 321

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07840820Non-segmental Vitiligo · China3Not yet recruitingNov 10, 2027480
NCT07695779Evaluation of QTc Interval · China1RecruitingSep 21, 202628
NCT07552012Uveitis · China2RecruitingFeb 28, 202740

How it is read

Names in the registry

  • “FXS5626 tablet”, 2 entries
  • “Intervention1: FXS5626 Tablets”, 1 entry
  • “Intervention2: FXS5626 Tablets”, 1 entry
  • “Intervention3: FXS5626 Tablets”, 1 entry
  • “Intervention4: FXS5626 Tablets”, 1 entry

Codes read as this program: FXS5626.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.